According to the Gamaleya Institute in Moscow and the Russian Direct Investment Fund, the Sputnik V vaccine is 97.6% effective against COVID-19 in a “real-world” evaluation based on data from 3.8 million citizens.
The current effectiveness rate is higher than the 91.6 percent rate recorded in results from a large-scale trial of Sputnik V published earlier this year in The Lancet medical journal, and it correlates favorably with data on the effectiveness of other COVID-19 vaccines.
The latest figures are focused on 3.8 million Russians who got both a first and a booster shot as part of Sputnik V’s nationwide rollout.The frequency of infection was estimated from the 35th day after the first injection, with a rate of 0.027 percent, according to the statement.
The information was gathered from the health ministry’s database of people who have been vaccinated, as well as a separate database of people who have been infected with COVID-19 in the region, according to the release.It stated that the rate of infection among unvaccinated adults was 1.1 percent for a period of time following the start of mass vaccination in Russia, without specifying the time period.
“This data confirms that Sputnik V demonstrates one of the best protection rates against coronavirus among all vaccines,” said Kirill Dmitriev, the head of the RDIF sovereign wealth fund, which is funding the vaccine.